BlackRock Advisors
IDXG

BlackRock Advisors’s Interpace Biosciences, Inc. Common Stock IDXG Stock Holding History

BlackRock Advisors’s Portfolio IDXG Stock Details IDXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-25
Closed -$6K – 3765
2014
Q3 		$6K Hold
25
– – ﹤0.01% 3620
2014
Q2 		$11K Hold
25
– – ﹤0.01% 3564
2014
Q1 		$12K Hold
25
– – ﹤0.01% 3519
2013
Q4 		$12K Hold
25
– – ﹤0.01% 3491
2013
Q3 		$12K Sell
25
-64
-72% -$30.7K ﹤0.01% 3428
2013
Q2 		$42K Buy
+89
New +$40.4K ﹤0.01% 3199

Other funds holding IDXG

HA
Heartland Advisors Milwaukee, Wisconsin $2.25B AUM 44.61% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PHS
Pekin Hardy Strauss Chicago, Illinois $1.14B AUM 37.36% 1-Year Est. Return
BlackRock Institutional Trust
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Ancora Advisors
Ancora Advisors Cleveland, Ohio $5.19B AUM 23.19% 1-Year Est. Return
LCM
Leonard Capital Management Vero Beach, Florida $5.25M AUM
Glenmede Trust
Glenmede Trust Philadelphia, Pennsylvania $22.7B AUM
Royce & Associates
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

BlackRock Advisors's IDXG Position: Q4 2014 in Review

BlackRock Advisors sold out of Interpace Biosciences, Inc. Common Stock (IDXG) in Q4 2014, closing a stake of 25 shares — an estimated $6K sold.

BlackRock Advisors first reported a position in IDXG in Q2 2013 and held it in 6 quarters. The position peaked at $42K in Q2 2013. 26 funds tracked by Wall St. Rank hold IDXG as of Q4 2014.

  • BlackRock Advisors reported no remaining Interpace Biosciences, Inc. Common Stock position as of Q4 2014 after selling out during the quarter.
  • BlackRock Advisors sold 25 Interpace Biosciences, Inc. Common Stock shares in Q4 2014, an estimated $6K.
  • BlackRock Advisors first reported a position in Interpace Biosciences, Inc. Common Stock in Q2 2013 and held it in 6 quarters.
  • BlackRock Advisors's Interpace Biosciences, Inc. Common Stock position peaked at $42K in Q2 2013.
  • 26 funds tracked by Wall St. Rank held Interpace Biosciences, Inc. Common Stock as of Q4 2014.

Based on BlackRock Advisors's 13F filing for Q4 2014, filed 9 Feb 2015.